Thanks Dr. T. The Pilar3 effectively being a combination of Pillar1 and Pillar 3 gives me confidence in the success of the trial.
Out of all the preclinical studies demonstrating Bisantrene as a potent FTO inhibitor, and the historical clinical results on AML, if the trial is designed rightly for the FTO, then we might see a better response in the FTO trial than the historical chemo trial, for the AML.
High chance of both being a success anyways, IMO..
Ann: Quarterly Activity Report & Appendix 4C, page-83
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
-0.050(2.58%) |
Mkt cap ! $313.4M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.84 | $572.1K | 304.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 574 | $1.89 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.91 | 7000 | 1 |
View Market Depth
| Last trade - 14.13pm 15/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |